Ergotamine tartrate
Cafergot, Ergostat, Wigraine, Wigrettes (ergotamine tartrate) is a small molecule pharmaceutical. Ergotamine tartrate was first approved as Cafergot on 1982-01-01. It is used to treat cluster headache, migraine disorders, and postpartum hemorrhage in the USA. It is known to target 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 1F, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 1E, and 5-hydroxytryptamine receptor 1D.
Download report
Favorite
Searched
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
nervous system diseases | D009422 |
urogenital diseases | D000091642 |
signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Caffeine
+
Ergotamine tartrate
Ergotamine tartrate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
MEDIHALER ERGOTAMINE | 3M | N-012102 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
cluster headache | HP_0012199 | D003027 | G44.00 |
migraine disorders | EFO_0003821 | D008881 | G43 |
postpartum hemorrhage | — | D006473 | O72 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
1 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | ERGOTAMINE TARTRATE |
INN | ergotamine |
Description | Ergotamine is a peptide ergot alkaloid that is dihydroergotamine in which a double bond replaces the single bond between positions 9 and 10. It has a role as a non-narcotic analgesic, a vasoconstrictor agent, a serotonergic agonist, an alpha-adrenergic agonist, a mycotoxin and an oxytocic. It is a conjugate base of an ergotamine(1+). |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.O=C(O)C(O)C(O)C(=O)O |
Identifiers
PDB | — |
CAS-ID | 113-15-5 |
RxCUI | 4025 |
ChEMBL ID | CHEMBL2448612 |
ChEBI ID | — |
PubChem CID | 8223 |
DrugBank | DB00696 |
UNII ID | PR834Q503T (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
HTR6
HTR6
HTR2C
HTR2C
HTR5A
HTR5A
HTR1F
HTR1F
HTR2B
HTR2B
HTR2A
HTR2A
HTR1E
HTR1E
HTR1D
HTR1D
Variants
Clinical Variant
No data
Financial
Migergot - Horizon Therapeutics Public
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,789 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cafergot, Ergomar , Migergot
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
31,520 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more